COVID-19 mRNA Vaccine Efficacy Wanes Over Time in RCC Cases
Strategies, such as booster doses, appear warranted in this population.
Strategies, such as booster doses, appear warranted in this population.
The decision to discontinue was based on data from pre-planned analyses of the phase 3 PIVOT-09 study and the phase 2 PIVOT-10 study.
The approval was based on data demonstrating that the biosimilar product and the reference product were highly similar, and that there were no clinically meaningful differences between the agents.
A review of regulatory and drug development status updates.
The investigational product targets CD70, which is highly expressed in renal cell carcinoma with limited normal tissue expression.
In a phase 1 trial, investigators tested whether an oral supplement containing a strain of Clostridium butyricum increases the abundance of certain gut bacteria known to be associated with a better response to immune checkpoint inhibitors.
Since patients with poor PS (≥2) were excluded from trials analyzing this new standard of care for mRCC treatment, the study aimed to assess the efficacy and safety of immune checkpoint combination therapy in this group of patients.
Investigators conducted a noninterventional, multicenter study (APOLON) in patients receiving frontline pazopanib therapy.
The case-based study aimed to analyze the prescribing behaviors of community oncologists treating patients with aRCC.
Treatment-related adverse events of any grade develop in the majority of patients who receive urologic cancer therapies based on immune checkpoint inhibitors, according to a study.